Professor David MacEwan BSc (Hons), PhD, FRSB, FBPhS, SFHEA
Chair of Molecular Pharmacology Pharmacology & Therapeutics
- +44 (0)151 794 5508
- Work email D.Macewan@liverpool.ac.uk
- Personal Websitehttp://www.researchgate.net/profile/David_MacEwan/
Research
Research Interests
See
http://www.researchgate.net/profile/David_MacEwan/
http://www.researcherid.com/rid/F-7044-2011
Current Research Group
Postdocs
Dr Rebecca Dawson
Dr Nicholas Harper
Dr Andrea Linford
Dr Adam Linley
Dr Vanessa Marensi
Postgrads (Primary Supervisor)
Mr Taha Alqahtani
Ms Sujitra Keadsanti
Ms Melanie Maerken
Mr Jonathan Po
Mr Simeon Ramsey
Ms Amy Robinson
Mr Niraj Shah
Postgrads (Secondary Supervision)
Mr Naif Alhumeed
Dr Eve Smith
Research Grants
Research Support Fees for Rehab Nawaf Shayem Alanazi
ROYAL EMBASSY OF SAUDI ARABIA CULTURAL BUREAU IN LONDON (UK)
March 2020 - February 2021
Kinomic reprogramming during clonal evolution and therapy resistance in chronic lymphocytic leukaemia
LEUKA (UK)
September 2018 - December 2020
Kinome profiling and mass cytometry as tools to detect rewiring of B cell receptor signalling in the malignant cells of chronic lymphocytic leukaemia patients taking ibrutinib
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
March 2019 - September 2022
Bench Fees - Taha Yahya T Alqahtani
ROYAL EMBASSY OF SAUDI ARABIA CULTURAL BUREAU IN LONDON (UK)
April 2017 - March 2020
Reversal of FLT3-ITD mutations in acute myeloid leukaemia and its effect on chemotherapy resistance
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
April 2017 - January 2021
Characterising the Bruton's kinase signaling nexus in leukaemia
NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)
September 2015 - September 2018
Determining ibrutinib's potential to treat human leukaemias - novel uses for an exciting new Bruton's tyrosine kinase (TTK) inhibitor
NORTH WEST CANCER RESEARCH FUND
September 2014 - June 2021